Related Experiment Video

Updated: Aug 21, 2026

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
07:42

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Published on: October 18, 2018

Beta blockers as anti-arrhythmic agents

Daejoon Anh1, Joseph E Marine

  • 1Section of Cardiac Electrophysiology, Henry Ford Heart and Vascular Institute, Detroit, MI 48202, USA.

Heart Failure Reviews
|November 2, 2004
PubMed

Insights

Beta-blockers offer survival benefits in heart failure, partly due to their anti-arrhythmic effects. Clinical trials show these drugs reduce sudden cardiac death and ventricular arrhythmias in patients with chronic heart failure.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Beta-adrenergic blocking agents (beta-blockers) are increasingly recognized for their role beyond traditional cardiovascular indications.
  • While not primarily classified as anti-arrhythmic drugs, emerging evidence suggests a significant contribution to mortality reduction in heart failure patients.
  • The anti-arrhythmic mechanism of beta-blockers in chronic heart failure warrants detailed investigation.

Purpose of the Study:

  • To review experimental and clinical evidence supporting the anti-arrhythmic actions of beta-blockers.
  • To analyze the outcomes of published clinical trials evaluating beta-blocker therapy in patients with chronic heart failure.
  • To determine if beta-blockers demonstrate a clinically significant anti-arrhythmic effect in this patient population.

Main Methods:

  • Systematic review of background experimental data on beta-blocker anti-arrhythmic properties.
  • Comprehensive analysis of results from published randomized controlled trials of beta-blockers in heart failure.
  • Evaluation of data on overall survival, sudden cardiac death, and ventricular arrhythmias.

Main Results:

  • A majority of reviewed trials demonstrated improved overall survival in patients treated with beta-blockers.
  • Significant reductions in sudden cardiac death and ventricular arrhythmias were observed with beta-blocker therapy.
  • While specific agent effects varied, the overall trial data support a clinically relevant anti-arrhythmic impact.

Conclusions:

  • Beta-blockers exhibit a clinically significant anti-arrhythmic effect in the management of chronic heart failure.
  • This anti-arrhythmic action contributes to the observed mortality benefit of beta-blockers in heart failure patients.
  • The findings support the continued use and investigation of beta-blockers for their combined cardiovascular and anti-arrhythmic benefits.

More Related Videos

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents10:53

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents

Published on: July 3, 2013

Related Concept Videos

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...